Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2014
Context: The company entered into a material definitive agreement involving a senior secured note and a planned rights offering to secure funding for operations and product development.
Key Financial Metrics and Obligations
- Debt Issuance: $1.75 million Senior Secured Note issued to Lambda Investors LLC.
- Interest Rate: 12% per annum (increases to 16% per annum upon default).
- Maturity Date: February 28, 2015.
- Collateral: First priority lien on all company property, including intellectual property.
- Transaction Fees: $140,000 sourcing/transaction fee (8%) and $75,000 for legal fees/expenses payable to Lambda Investors.
- Planned Equity Raise: $3 million rights offering at an expected price of $0.60 per share.
- Liquidity/Cash Flow: The filing does not provide current cash balance or operating cash flow figures; it indicates a reliance on the rights offering proceeds to prepay the note.
Material Changes and Covenants
The company has incurred a new direct financial obligation and is subject to restrictive covenants as long as the note remains outstanding. These covenants restrict the company's ability to:
- Merge with another company.
- Sell a material amount of assets.
- Incur additional indebtedness.
- Repay existing indebtedness (other than the Note).
- Declare or pay dividends.
Prepayment Requirement: The company must prepay the note using proceeds from the rights offering, other equity/debt financing, asset sales, or new indebtedness prior to maturity.
Outlook, Risks, and Contingencies
Management Commentary: The company intends to conduct a $3 million rights offering. Lambda Investors has agreed to purchase unsubscribed shares if the offering is not fully subscribed and has extended the expiration of its existing warrants to five years post-closing.
Material Risks:
- Going Concern: Significant risk that the company may not be able to continue as a going concern if funding is not secured.
- Default Consequences: Default on the note could result in the lender foreclosing on substantially all assets, halting operations.
- Offering Failure: Inability to complete the rights offering could result in an inability to continue business operations.
- Regulatory and Product Risks: Potential for product recalls, FDA enforcement actions, and liability claims related to water filtration and renal failure therapy products.
- Market Acceptance: Challenges in obtaining market acceptance for the HDF system and selling products at competitive prices.
Investor Verification Checklist
- Verify the effectiveness of the Form S-1 registration statement for the $3 million rights offering.
- Confirm the company's current cash position and runway to determine if the $1.75 million note is sufficient until the rights offering closes.
- Review the full text of the Senior Secured Note (Exhibit 10.1) for specific default triggers and foreclosure procedures.
- Assess the status of the voluntary recalls announced in October 2013 and any resulting regulatory or legal proceedings.
- Monitor the subscription rate of the rights offering to determine if Lambda Investors will be required to purchase unsubscribed shares.